Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Conditions:   Leukemia;   Brain Tumor;   Solid Tumor;   Lymphoma Interventions:   Drug: ALRN-6924;   Drug: Cytarabine Sponsor:   Dana-Farber Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials